RBC Capital Maintains Outperform on Biohaven, Lowers Price Target to $58

Benzinga · 11/25 17:26
RBC Capital analyst Leonid Timashev maintains Biohaven (NYSE:BHVN) with a Outperform and lowers the price target from $66 to $58.